Real-World study checks how oral semaglutide works for diabetes

NCT ID NCT05230615

First seen Jun 24, 2026 · Last updated Jun 24, 2026

Summary

This study looked at how once-daily oral semaglutide (Rybelsus) affects blood sugar and body weight in adults with type 2 diabetes in Italy. Researchers followed 458 patients for about 8-10 months as they took the medication as part of their normal care. The goal was to see if the drug helps lower blood sugar levels in everyday practice.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • IRCCS MultiMedica

    Sesto San Giovanni, Italy

  • Master Centre for Italy

    Rome, 00144, Italy

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

oral semaglutide (Rybelsus)

What this could lead to

If successful, this study could confirm that oral semaglutide helps control blood sugar and weight in real-world settings, supporting its use for type 2 diabetes management.

What could go wrong

This is an observational study, not a controlled trial, so results may be influenced by other factors. It is also completed, so findings are already known and may not lead to new treatments.

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.